Biomarkers unbound

Controversies surrounding government walk-in rights or patent eligibility that grabbed headlines in recent weeks presage broader changes in biomarker patenting In recent weeks, biotech patenting has been shaken by two high-profile legal decisions. The good news is that the sheer scale and variety of...

Full description

Saved in:
Bibliographic Details
Published inNature biotechnology Vol. 30; no. 5; p. 372
Format Journal Article
LanguageEnglish
Published New York Nature Publishing Group US 01.05.2012
Nature Publishing Group
Subjects
631/61
631/67/1857
706/703/270
Agriculture
Bioinformatics
Biomarkers
Biomarkers - metabolism
Biomedical and Life Sciences
Biomedical Engineering/Biotechnology
Biomedical research
Biomedicine
Biotechnology
Biotechnology - legislation & jurisprudence
Biotechnology - trends
DNA - chemistry
editorial
Humans
India
Life Sciences
Patents as Topic
Sequence Analysis, DNA
United States
United States
India
Online AccessGet full text
ISSN1087-0156
1546-1696
1546-1696
DOI10.1038/nbt.2221

Cover

More Information
Summary:Controversies surrounding government walk-in rights or patent eligibility that grabbed headlines in recent weeks presage broader changes in biomarker patenting In recent weeks, biotech patenting has been shaken by two high-profile legal decisions. The good news is that the sheer scale and variety of biomedical data ushered in by evidence-based healthcare will create a myriad of exciting opportunities for biotech inventors and/or patents.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Editorial-4
ObjectType-Commentary-3
content type line 23
ObjectType-Editorial-2
ObjectType-Commentary-1
ISSN:1087-0156
1546-1696
1546-1696
DOI:10.1038/nbt.2221